Research Article

Indian spices and Caffeine treatment for Obesity and Cardiovascular disease

Ian James Martins*

Published: 01/31/2018 | Volume 2 - Issue 1 | Pages: 010-014

Editorial

The global obesity epidemic that was previously reported [1,2] is now to worsen with obesity to double in 73 countries around the world [3,4]. Improving the health of obese individuals by dietary restriction, anti-obese foods and increased physical activity [1] has not reduced the global obesity epidemic. Obesity is linked to nonalcoholic fatty liver disease (NAFLD) [5,6] with complications relevant to the metabolic syndrome and cardiovascular disease [7]. Appetite control has become critical to endocrinology and metabolism with the apelinergic pathway and nuclear receptor Sirtuin 1 (Sirt 1) now connected to the endocrine system [8] and critical to metabolism. The apelin-Sirt 1 interaction involves nitric oxide (NO) [9] that is now considered as the defect [10] in the interaction between the peptide apelin and calorie sensitive gene Sirt 1 involved in NO imbalances in the adipose tissue, liver and the brain.

Read Full Article HTMLDOI: 10.29328/journal.acem.1001005Cite this Article

References

  1. Martins IJ. Appetite dysregulation and obesity in Western Countries. LAP LAMBERT Academic Publishing. 2013. Ref.: https://goo.gl/9Q9tnW
  2. Martins IJ. Induction of NAFLD with Increased Risk of Obesity and Chronic Diseases in Developed Countries. OJEM Diseases. 2014; 4: 90-110. Ref.: https://goo.gl/uHz7H6
  3. An R, Ji M, Zhang S. Global warming and obesity: a systematic review. Obes Rev. 2018; 19: 150-163. Ref.: https://goo.gl/i9GpEv
  4. Friedrich MJ. Global Obesity Epidemic Worsening. JAMA. 2017; 318:603. Ref.: https://goo.gl/79iEGw
  5. Fabbrini E, Sullivan S, Klein S. Obesity and non-alcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010; 51: 679-689. Ref.: https://goo.gl/ebJjFZ
  6. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014; 28: 637-653. Ref.: https://goo.gl/ecCzVn
  7. Kim SH, Després JP, Koh KK. Obesity and cardiovascular disease: friend or foe? Eur Heart J. 2016; 37: 3560-3568. Ref.: https://goo.gl/4ZjohT
  8. Martins IJ. Nutritional diets accelerate amyloid beta metabolism and prevent the induction of chronic diseases and Alzheimer’s disease. J Endocrinol and Metab. Photon. 2015; 1-48.
  9. Martins IJ. Apelin and Sirtuin 1 dysregulation induce Endocrine and Metabolic Disorders in Chronic disease. GJEM. 2017; 1:1. Ref.: https://goo.gl/Z3TmLM
  10. Martins IJ. Apelinergic System Defects with Relevance to Mental Disorders in Diabetes. World J Psychiatry Ment Health Res. 2017; 1: 1001. Ref.: https://goo.gl/q3yoRr
  11. Martins IJ. Unhealthy Nutrigenomic Diets Accelerate NAFLD and Adiposity in Global communities. J Mol Genet Med. 2015; 9: 1-8. Ref.: https://goo.gl/mWnRMX
  12. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2007; 13: 3540-3553. Ref.: https://goo.gl/56N5AG
  13. Martins IJ. Avasimibe and Sirt 1 Activators Reverse NAFLD and Obesity. Nov Appro Drug Des Dev. 2017; 1: 1-2.
  14. Adan RA. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci. 2013; 36: 133-40. Ref.: https://goo.gl/1n2Ha4
  15. García-Ruiz C, Baulies A, Mari M, García-Rovés PM, Fernandez-Checa JC. Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: cause or consequence? Free Radic Res. 2013; 47: 854-868. Ref.: https://goo.gl/iwfFy7
  16. Martins IJ. Defective Inter­play between Adipose Tissue and Immune System Induces Non Alcoholic Fatty Liver Disease. Updates Nutr Disorders Ther. 2017; 1: 3.1. Ref.: https://goo.gl/YQSnyd
  17. Martins IJ. Autoimmune disease and mitochondrial dysfunction in chronic diseases. Res Chron Dis. 2017; 1: 10-12. Ref.: https://goo.gl/LXak5D
  18. Mazzucotelli A, Ribet C, Castan-Laurell I, Daviaud D, Guigné C, et al. The transcriptional co-activator PGC-1alpha up regulates apelin in human and mouse adipocytes. Regul Pept. 2008; 150: 33-37. Ref.: https://goo.gl/rJtdLa
  19. Kilic U, Gok O, Bacaksiz A, Izmirli M, Elibol-Can B, et al. SIRT1 gene polymorphisms affect the protein expression in cardiovascular diseases. PLoS One. 2014; 9: 90428. Ref.: https://goo.gl/3Y8B9Y
  20. Biason-Lauber A, Böni-Schnetzler M, Hubbard BP, Bouzakri K, Brunner A, et al. Identification of a SIRT1 Mutation in a Family with Type 1 Diabetes. Cell Metab. 2013; 17: 448-455. Ref.: https://goo.gl/xjz2Qm
  21. Hughes JW, Herold KC. Novel SIRT1 Mutation Linked to Autoimmune Diabetes in Humans. Cell Metab. 2013; 17: 311-312. Ref.: https://goo.gl/NQ5rtv
  22. Martins IJ. Type 3 diabetes with links to NAFLD and Other Chronic Diseases in the Western World. Int J Diab and Metab Disord. 2016; 1: 1-5. Ref.: https://goo.gl/hGqXFe
  23. Martins IJ. Heat shock gene Sirtuin 1 regulates post-prandial lipid metabolism with relevance to nutrition and appetite regulation in diabetes. Int J Diab Clin Diagn. 2016; 3: 1-3. Ref.: https://goo.gl/WdzCgC
  24. Martins IJ. Regulation of Core Body Temperature and the Immune System Determines Species Longevity. Curr Updates Gerontol. 2017; 1: 6. Ref.: https://goo.gl/y3tCqE
  25. Martins IJ. Caffeine Consumption and Induction of Obesity in the Developed World. Ann Obes Disord. 2017; 2: 1018. https://goo.gl/km1Unh
  26. Martins IJ. Nutrition Therapy Regulates Caffeine Metabolism with Relevance to NAFLD and Induction of Type 3 Diabetes. J Diabetes Metab Disord. 2017; 4: 019. Ref.: https://goo.gl/ukJA55
  27. Martins IJ. Caffeine with Links to NAFLD and Accelerated Brain Aging. In Tech Open. 2017. Ref.: https://goo.gl/8dZsGD
  28. Martins IJ. Caffeine consumption with Relevance to Type 3 diabetes and accelerated brain aging. Res Reveiws: Neurosci. 2016; 1: 1-5. Ref.: https://goo.gl/qbUzY8
  29. Martins IJ. Indian Spices and Unhealthy Diets interfere with Drug Therapy in Diabetes and Neurodegenerative Diseases. Nov Appro Drug Des Dev. 2018; 3: 1-4. Ref.: https://goo.gl/H5YZN4
  30. Ejaz A, Wu D, Kwan P, Meydani M. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr. 2009; 139: 919-925. Ref.: https://goo.gl/XspCuq
  31. Teich T, Pivovarov JA, Porras DP, Dunford EC, Riddell MC. Curcumin limits weight gain, adipose tissue growth, and glucose intolerance following the cessation of exercise and caloric restriction in rats. J Appl Physiol (1985). 2017; 123: 1625-1634. Ref.: https://goo.gl/djjGKY
  32. Wang S, Wang X, Ye Z, Xu C, Zhang M, et al. Curcumin promotes browning of white adipose tissue in a norepinephrine-dependent way. Biochem Biophys Res Commun. 2015; 466: 247-253. Ref.: https://goo.gl/SuiirT
  33. Bradford PG. Curcumin and obesity. Biofactors. 2013; 39: 78-87. Ref.: https://goo.gl/wkqhdv
  34. Inzaugarat ME, De Matteo E, Baz P, Lucero D, García CC, et al. New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans. PLoS ONE. 2017; 12: e0172900. Ref.: https://goo.gl/C5CdXU
  35. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, et al. Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Drug Res (Stuttg). 2017; 67: 244-251. Ref.: https://goo.gl/QzbkiS
  36. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, et al. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytother Res. 2016; 30: 1540-1548. Ref.: https://goo.gl/oBQ7j7
  37. Baliga MS, Jagetia GC, Rao SK, Babu K. Evaluation of nitric oxide scavenging activity of certain spices in vitro: a preliminary study. Nahrung. 2003; 47: 261-264. Ref.: https://goo.gl/97anfL
  38. Kalaivani P, Saranya RB, Ramakrishnan G, Ranju V, Sathiya S, et al. Cuminum cyminum, a dietary spice, attenuates hypertension via endothelial nitric oxide synthase and NO pathway in renovascular hypertensive rats. Clin Exp Hypertens. 2013; 35: 534-542. Ref.: https://goo.gl/R5V2P9
  39. Nakatake R, Hishikawa H, Matsuhima H, Nakamura Y, Ishizaki M, et al. Curcumin protects liver inflammation by suppressing expression of inducible nitric oxide synthase in primary cultured rat hepatocytes. Functional Foods in Health and Disease. 2017; 7: 716-734. Ref.: https://goo.gl/CyxUaA
  40. Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, et al. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids. 2003; 25: 437-444. Ref.: https://goo.gl/kZ3LvS
  41. Mait P, Manna J. Activation of Heat Shock Proteins by Nanocurcumin to Prevent Neurodegenerative Diseases. Brain Disord Ther. 2014; 3:139. Ref.: https://goo.gl/vSsgkU
  42. Martins IJ. Calorie Sensitive Anti-Aging Gene Regulates Hepatic Amyloid Beta Clearance in Diabetes and Neurodegenerative Diseases. EC Nutrition ECO. 2017; 01: 30-32. Ref.: https://goo.gl/FswPeB
  43. Shatwan IA, Ahmed LA, Badkook MM. Effect of barley flour, crude cinnamon, and their combination on glycemia, dyslipidemia, and adipose tissue hormones in type 2 diabetic rats. J Med Food. 2013; 16: 656-662. Ref.: https://goo.gl/uvZt6j
  44. Lopes BP, Gaique TG, Souza LL, Paula GS, Kluck GE, et al. Cinnamon extract improves the body composition and attenuates lipogenic processes in the liver and adipose tissue of rats. Food Funct. 2015; 6: 3257-3265. Ref.: https://goo.gl/5bCMBm
  45. Kwan HY, Wu J, Su T, Chao X-C, Liu B, et al. Cinnamon induces browning in subcutaneous adipocytes. Scientific Reports. 2017; 7: 2447. Ref.: https://goo.gl/NGzgYy
  46. Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 2014; 34: 143-148. Ref.: https://goo.gl/hCkdx7
  47. Hekmatdoost A. Prevention of Nonalcoholic Fatty Liver Disease (NAFLD) Progression to Nonalcoholic Steatohepatitis (NASH) by Modification of Lifestyle and Dietary Supplements. J Clin Nutr Diet. 2016; 2: 2. Ref.: https://goo.gl/rRi7VN
  48. Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 2015; 7: 204-212. Ref.: https://goo.gl/C6dmCa
  49. Martins IJ. Insulin Therapy Inactivation is connected to NAFLD and Diabetes Severity Index. J Diab Clin Stud. 2017; 1: 001-003. Ref.: https://goo.gl/zXAMW3
  50. Wilson PW, Bloom HL. Caffeine Consumption and Cardiovascular Risks: Little Cause for Concern. J Am Heart Assoc. 2016; 5: 003089. Ref.: https://goo.gl/mQymj7
  51. Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB. Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation. 2014; 129: 643-659. Ref.: https://goo.gl/eY1FgP
  52. Martins IJ. Genomic Medicine and Acute Cardiovascular Disease Progression. Res Chron Dis. 2018.